{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:39:55Z","timestamp":1794649195729,"version":"4.9.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41589-025-01978-1","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:04:19Z","timestamp":1754903059000},"page":"260-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-3945","authenticated-orcid":false,"given":"Nathan L.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-9371","authenticated-orcid":false,"given":"Jiewei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0330","authenticated-orcid":false,"given":"Min","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian E.","family":"Gadbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C. M.","family":"Gulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-202X","authenticated-orcid":false,"given":"Alyssa L.","family":"Verano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara R.","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Teng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8668-2449","authenticated-orcid":false,"given":"David A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Manor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G.","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Tiriac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-9748","authenticated-orcid":false,"given":"Eric S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-7617","authenticated-orcid":false,"given":"Fleur M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"1978_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1978_CR2","doi-asserted-by":"publisher","first-page":"360490","DOI":"10.1200\/JCO.2022.40.36_suppl.360490","volume":"40","author":"JH Strickler","year":"2022","unstructured":"Strickler, J. H. et al. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: a phase I\/II study evaluating efficacy and safety. J. Clin. Oncol. 40, 360490\u2013360490 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1978_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19, 533\u2013552 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1978_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar, S. R., Velcheti, V., Neel, B. G. & Wong, K. K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol. 19, 637\u2013655 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1978_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41589-024-01565-w","volume":"20","author":"Q Zheng","year":"2024","unstructured":"Zheng, Q., Zhang, Z., Guiley, K. Z. & Shokat, K. M.Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D. Nat. Chem. Biol. 20, 1114\u20131122 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1978_CR6","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1021\/jacs.2c05377","volume":"144","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z. & Shokat, K. M. Chemoselective covalent modification of K-Ras(G12R) with a small molecule electrophile. J. Am. Chem. Soc. 144, 15916\u201315921 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1978_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41589-022-01065-9","volume":"18","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Guiley, K. Z. & Shokat, K. M. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Nat. Chem. Biol. 18, 1177\u20131183 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1978_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1978_CR9","doi-asserted-by":"publisher","first-page":"S751","DOI":"10.1016\/S1556-0864(21)01941-9","volume":"16","author":"GJ Riely","year":"2021","unstructured":"Riely, G. J. et al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J. Thorac. Oncol. 16, S751\u2013S752 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1978_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2022","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1978_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"1978_CR12","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay, K. C. M. et al. Dual Inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001\u20133012 (2023).","journal-title":"Cancer Res."},{"key":"1978_CR13","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1978_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"1978_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann, T., Sers, C., Der, C. J. & Papke, B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer 11, 91\u2013116 (2025).","journal-title":"Trends Cancer"},{"key":"1978_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100131","volume":"1","author":"WS Brown","year":"2020","unstructured":"Brown, W. S. et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1\/2 complexes in pancreatic cancer. Cell Rep. Med 1, 100131 (2020).","journal-title":"Cell Rep. Med"},{"key":"1978_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00942-5","volume":"8","author":"MD Muzumdar","year":"2017","unstructured":"Muzumdar, M. D. et al. Survival of pancreatic cancer cells lacking KRAS function. Nat. Commun. 8, 1090 (2017).","journal-title":"Nat. Commun."},{"key":"1978_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07472-8","volume":"9","author":"N Santana-Codina","year":"2018","unstructured":"Santana-Codina, N. et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat. Commun. 9, 4945 (2018).","journal-title":"Nat. Commun."},{"key":"1978_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumor-selective activity of RAS\u2013GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"1978_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628\u2013632 (2014).","journal-title":"Nature"},{"key":"1978_CR21","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1016\/j.celrep.2020.03.021","volume":"30","author":"N Santana-Codina","year":"2020","unstructured":"Santana-Codina, N. et al. Defining and targeting adaptations to oncogenic KRAS(G12C) inhibition using quantitative temporal proteomics. Cell Rep. 30, 4584\u20134599 e4584 (2020).","journal-title":"Cell Rep."},{"key":"1978_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges, H. R., Jones, A. J., Pollak, M. N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462, 475\u2013487 (2014).","journal-title":"Biochem. J."},{"key":"1978_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat. Neurosci. 3, 1301\u20131306 (2000).","journal-title":"Nat. Neurosci."},{"key":"1978_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/toxsci\/kfn092","volume":"104","author":"M Sanchez","year":"2008","unstructured":"Sanchez, M., Gastaldi, L., Remedi, M., Caceres, A. & Landa, C. Rotenone-induced toxicity is mediated by Rho-GTPases in hippocampal neurons. Toxicol. Sci. 104, 352\u2013361 (2008).","journal-title":"Toxicol. Sci."},{"key":"1978_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29, 115\u2013126 (2023).","journal-title":"Nat. Med."},{"key":"1978_CR26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1021\/bi00628a023","volume":"16","author":"M Wu","year":"1977","unstructured":"Wu, M., Arimura, G. K. & Yunis, A. A. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry 16, 1908\u20131913 (1977).","journal-title":"Biochemistry"},{"key":"1978_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cmet.2016.08.017","volume":"24","author":"JD Arroyo","year":"2016","unstructured":"Arroyo, J. D. et al. A genome-wide CRISPR death screen identifies genes essential for oxidative phosphorylation. Cell Metab. 24, 875\u2013885 (2016).","journal-title":"Cell Metab."},{"key":"1978_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103805","volume":"29","author":"KR Sharma","year":"2023","unstructured":"Sharma, K. R., Colvis, C. M., Rodgers, G. P. & Sheeley, D. M. Illuminating the druggable genome: pathways to progress. Drug Discov. Today 29, 103805 (2023).","journal-title":"Drug Discov. Today"},{"key":"1978_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-021-00245-x","volume":"20","author":"M Schneider","year":"2021","unstructured":"Schneider, M. et al. The PROTACtable genome. Nat. Rev. Drug Discov. 20, 789\u2013797 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1978_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/mp.2017.60","volume":"23","author":"R Harripaul","year":"2018","unstructured":"Harripaul, R. et al. Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. Mol. Psychiatry 23, 973\u2013984 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1978_CR31","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1093\/hmg\/ddy220","volume":"27","author":"Z Fattahi","year":"2018","unstructured":"Fattahi, Z. et al. Biallelic missense variants in ZBTB11 can cause intellectual disability in humans. Hum. Mol. Genet 27, 3177\u20133188 (2018).","journal-title":"Hum. Mol. Genet"},{"key":"1978_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19205-x","volume":"11","author":"BC Wilson","year":"2020","unstructured":"Wilson, B. C. et al. Intellectual disability-associated factor ZBTB11 cooperates with NRF-2\/GABP to control mitochondrial function. Nat. Commun. 11, 5469 (2020).","journal-title":"Nat. Commun."},{"key":"1978_CR33","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096\u20131101 (2015).","journal-title":"Science"},{"key":"1978_CR34","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1126\/science.aac7557","volume":"350","author":"VA Blomen","year":"2015","unstructured":"Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092\u20131096 (2015).","journal-title":"Science"},{"key":"1978_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 (2017).","journal-title":"Cell"},{"key":"1978_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","volume":"104","author":"R Tian","year":"2019","unstructured":"Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239\u2013255 (2019).","journal-title":"Neuron"},{"key":"1978_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/ars.2009.2598","volume":"12","author":"A Terman","year":"2010","unstructured":"Terman, A., Kurz, T., Navratil, M., Arriaga, E. A. & Brunk, U. T. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial\u2013lysosomal axis theory of aging. Antioxid. Redox Signal 12, 503\u2013535 (2010).","journal-title":"Antioxid. Redox Signal"},{"key":"1978_CR38","doi-asserted-by":"publisher","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","journal-title":"Science"},{"key":"1978_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1021\/acschembio.4c00152","volume":"19","author":"V Vetma","year":"2024","unstructured":"Vetma, V. et al. Confounding factors in targeted degradation of short-lived proteins. ACS Chem. Biol. 19, 1484\u20131494 (2024).","journal-title":"ACS Chem. Biol."},{"key":"1978_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.611","volume":"2","author":"NL Tran","year":"2022","unstructured":"Tran, N. L., Leconte, G. A. & Ferguson, F. M. Targeted protein degradation: design considerations for PROTAC development. Curr. Protoc. 2, e611 (2022).","journal-title":"Curr. Protoc."},{"key":"1978_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-1-0716-1665-9_8","volume":"2365","author":"SD Mahan","year":"2021","unstructured":"Mahan, S. D., Riching, K. M., Urh, M. & Daniels, D. L. Kinetic detection of E3:PROTAC:target ternary complexes using NanoBRET technology in live cells. Methods Mol. Biol. 2365, 151\u2013171 (2021).","journal-title":"Methods Mol. Biol."},{"key":"1978_CR42","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2021014701","volume":"139","author":"W Wu","year":"2022","unstructured":"Wu, W. et al. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood 139, 2024\u20132037 (2022).","journal-title":"Blood"},{"key":"1978_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.adk6129","volume":"385","author":"PY Ting","year":"2024","unstructured":"Ting, P. Y. et al. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Science 385, 91\u201399 (2024).","journal-title":"Science"},{"key":"1978_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"1978_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1978_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35593-8","volume":"13","author":"ZC Drake","year":"2022","unstructured":"Drake, Z. C., Seffernick, J. T. & Lindert, S. Protein complex prediction using Rosetta, AlphaFold, and mass spectrometry covalent labeling. Nat. Commun. 13, 7846 (2022).","journal-title":"Nat. Commun."},{"key":"1978_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549\u2013553 (2022).","journal-title":"Science"},{"key":"1978_CR48","doi-asserted-by":"publisher","first-page":"7980","DOI":"10.1021\/jp073337x","volume":"111","author":"D Kim","year":"2007","unstructured":"Kim, D., Lee, E. C., Kim, K. S. & Tarakeshwar, P. Cation\u2013\u03c0\u2013anion interaction: a theoretical investigation of the role of induction energies. J. Phys. Chem. A 111, 7980\u20137986 (2007).","journal-title":"J. Phys. Chem. A"},{"key":"1978_CR49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2011","unstructured":"Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385\u2013388 (2011).","journal-title":"Nature"},{"key":"1978_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature10602","volume":"481","author":"CM Metallo","year":"2011","unstructured":"Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380\u2013384 (2011).","journal-title":"Nature"},{"key":"1978_CR51","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.celrep.2014.04.037","volume":"7","author":"AR Mullen","year":"2014","unstructured":"Mullen, A. R. et al. Oxidation of \u03b1-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7, 1679\u20131690 (2014).","journal-title":"Cell Rep."},{"key":"1978_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3236","volume":"4","author":"SM Fendt","year":"2013","unstructured":"Fendt, S. M. et al. Reductive glutamine metabolism is a function of the \u03b1-ketoglutarate to citrate ratio in cells. Nat. Commun. 4, 2236 (2013).","journal-title":"Nat. Commun."},{"key":"1978_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/bjc.2014.272","volume":"111","author":"G Cheng","year":"2014","unstructured":"Cheng, G. et al. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br. J. Cancer 111, 85\u201393 (2014).","journal-title":"Br. J. Cancer"},{"key":"1978_CR54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"1978_CR55","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1074\/jbc.RA120.013366","volume":"295","author":"A Tsuji","year":"2020","unstructured":"Tsuji, A., Akao, T., Masuya, T., Murai, M. & Miyoshi, H. IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism. J. Biol. Chem. 295, 7481\u20137491 (2020).","journal-title":"J. Biol. Chem."},{"key":"1978_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"1978_CR57","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. CRBN (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"1978_CR58","doi-asserted-by":"publisher","first-page":"e38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane radial ray syndrome. eLife 7, e38430 (2018).","journal-title":"eLife"},{"key":"1978_CR59","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-0716-3287-1_22","volume":"2683","author":"D Pre","year":"2023","unstructured":"Pre, D., Wooten, A. T., Zhou, H., Neil, A. & Bang, A. G. Assaying chemical long-term potentiation in human iPSC-derived neuronal networks. Methods Mol. Biol. 2683, 275\u2013289 (2023).","journal-title":"Methods Mol. Biol."},{"key":"1978_CR60","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.stemcr.2022.07.012","volume":"17","author":"D Pre","year":"2022","unstructured":"Pre, D. et al. Development of a platform to investigate long-term potentiation in human iPSC-derived neuronal networks. Stem Cell Rep. 17, 2141\u20132155 (2022).","journal-title":"Stem Cell Rep."},{"key":"1978_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.647877","volume":"15","author":"F Puppo","year":"2021","unstructured":"Puppo, F., Pre, D., Bang, A. G. & Silva, G. A. Super-selective reconstruction of causal and direct connectivity with application to in vitro iPSC neuronal networks. Front. Neurosci. 15, 647877 (2021).","journal-title":"Front. Neurosci."},{"key":"1978_CR62","doi-asserted-by":"publisher","first-page":"dmm031906","DOI":"10.1242\/dmm.031906","volume":"11","author":"SP Sherman","year":"2018","unstructured":"Sherman, S. P. & Bang, A. G.High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell-derived neurons. Dis. Model. Mech. 11, dmm031906 (2018).","journal-title":"Dis. Model. Mech."},{"key":"1978_CR63","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716\u2013735 (2017).","journal-title":"Cancer Discov."},{"key":"1978_CR64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.leukres.2017.09.021","volume":"62","author":"K Henkenius","year":"2017","unstructured":"Henkenius, K. et al. Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leuk. Res. 62, 56\u201363 (2017).","journal-title":"Leuk. Res."},{"key":"1978_CR65","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee, K. M. et al. Myc and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 26, 633\u2013647 (2017).","journal-title":"Cell Metab."},{"key":"1978_CR66","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","volume":"15","author":"P Navarro","year":"2016","unstructured":"Navarro, P. et al. Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep. 15, 2705\u20132718 (2016).","journal-title":"Cell Rep."},{"key":"1978_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze, R. et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell 36, 369\u2013384 (2019).","journal-title":"Cancer Cell"},{"key":"1978_CR68","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz, E. M. et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med. 23, 1234\u20131240 (2017).","journal-title":"Nat. Med."},{"key":"1978_CR69","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF. Cancer Cell 23, 302\u2013315 (2013).","journal-title":"Cancer Cell"},{"key":"1978_CR70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338 (2015).","journal-title":"Cell"},{"key":"1978_CR71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/acschembio.7b00549","volume":"13","author":"MK Schwinn","year":"2018","unstructured":"Schwinn, M. K. et al. CRISPR-mediated tagging of endogenous proteins with a luminescent peptide. ACS Chem. Biol. 13, 467\u2013474 (2018).","journal-title":"ACS Chem. Biol."},{"key":"1978_CR72","unstructured":"Romero, N., Rogers, G., Neilson, A. & Dranka, B. P. Quantifying Cellular ATP Production Rate Using Agilent Seahorse XF Technology (Agilent, 2018)."},{"key":"1978_CR73","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.15252\/embr.202256380","volume":"24","author":"BR Desousa","year":"2023","unstructured":"Desousa, B. R. et al. Calculation of ATP production rates using the Seahorse XF analyzer. EMBO Rep. 24, e56380 (2023).","journal-title":"EMBO Rep."},{"key":"1978_CR74","doi-asserted-by":"publisher","first-page":"D966","DOI":"10.1093\/nar\/gkae1078","volume":"53","author":"JM Mudge","year":"2025","unstructured":"Mudge, J. M. et al. GENCODE 2025: reference gene annotation for human and mouse. Nucleic Acids Res. 53, D966\u2013D975 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1978_CR75","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1978_CR76","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1978_CR77","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1152\/ajpendo.00457.2019","volume":"318","author":"A Chaudhry","year":"2020","unstructured":"Chaudhry, A., Shi, R. & Luciani, D. S. A pipeline for multidimensional confocal analysis of mitochondrial morphology, function, and dynamics in pancreatic \u03b2-cells. Am. J. Physiol. Endocrinol. Metab. 318, E87\u2013E101 (2020).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1978_CR78","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1093\/bioinformatics\/btl526","volume":"22","author":"B Bunk","year":"2006","unstructured":"Bunk, B. et al. MetaQuant: a tool for the automatic quantification of GC\/MS-based metabolome data. Bioinformatics 22, 2962\u20132965 (2006).","journal-title":"Bioinformatics"},{"key":"1978_CR79","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41596-023-00950-4","volume":"19","author":"JD Ewald","year":"2024","unstructured":"Ewald, J. D. et al. Web-based multi-omics integration using the Analyst software suite. Nat. Protoc. 19, 1467\u20131497 (2024).","journal-title":"Nat. Protoc."},{"key":"1978_CR80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"1978_CR81","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1021\/jasms.3c00154","volume":"34","author":"M Ma","year":"2023","unstructured":"Ma, M. et al. Proteome-wide profiling of asymmetric dimethylated arginine in human breast tumors. J. Am. Soc. Mass Spectrom. 34, 1692\u20131700 (2023).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"1978_CR82","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-025-01978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-025-01978-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-025-01978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:02:46Z","timestamp":1769745766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-025-01978-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1038\/s41589-025-01978-1","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M.F., E.S.W., J.J. and N.L.T. are inventors on a patent application related to this work (US 63\/515,472). The E.S.W. lab receives or has received research resources in kind from SK Life Sciences. F.M.F. is a scientific cofounder and equity holder in Proximity Therapeutics and was previously a scientific advisory board member of Triana Biomedicines. F.M.F. is or was recently a consultant or received speaking honoraria from RA Capital, Tocris BioTechne, Eli Lilly, Amgen, Neomorph and Plexium. The F.M.F. lab receives or has received research funding, travel funding or resources in kind from Ono Pharmaceutical, Eli Lilly, Promega and Merck. F.M.F.\u2019s interests have been reviewed and approved by UCSD in accordance with its conflict-of-interest policies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}